| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | NOVO-NORDISK A S | 136,610 | 6,236,000 | 0.26% | ||
| 52 | INOGEN INC COM | 283,410 | 4,679,000 | 0.19% | ||
| 53 | ACCURAY INCORPORATED COM | 483,739 | 4,644,000 | 0.19% | ||
| 54 | DEXCOM INC | 71,346 | 2,951,000 | 0.12% | ||
| 55 | NOVARTIS A G | 31,200 | 2,653,000 | 0.11% | ||
| 56 | ELEVEN BIOTHERAPEUTICS INC | 50,000 | 812,000 | 0.03% | ||
| 57 | ANTHERA PHARMACEUTICALS I | 221,462 | 742,000 | 0.03% | ||
| 58 | GLYCOMIMETICS INC | 44,587 | 728,000 | 0.03% | ||
| 59 | TANDEM DIABETES CARE INC COM | 30,100 | 665,000 | 0.03% | ||
| 60 | FIVE PRIME THERAPEUTICS INC | 32,372 | 636,000 | 0.03% | ||
| 61 | LPATH INC | 126,464 | 601,000 | 0.02% | ||
| 62 | Tekmira Pharmaceuticals Corp. | 27,500 | 591,000 | 0.02% | ||
| 63 | AQUINOX PHARMACEUTICALS INC | 30,000 | 382,000 | 0.02% | ||
| 64 | Wuxi Pharmatech Inc ADR | 6,690 | 247,000 | 0.01% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001104659-14-038454, filed 2014.05.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
